This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical results on this page are restricted to the ClinicalTrials.gov record.
1. Trial at a Glance
PIONEER AF-PCI was a randomized, parallel, open-label phase 3 trial enrolling 2124 participants with atrial fibrillation who underwent percutaneous coronary intervention. The trial compared two rivaroxaban-based strategies with a vitamin K antagonist strategy, with clinically significant bleeding as the registered primary endpoint through Month 12.
| Feature | PIONEER AF-PCI |
|---|---|
| Phase | Phase 3 |
| Conditions | Atrial Fibrillation; Percutaneous Coronary Intervention |
| Design | Randomized, parallel, unmasked |
| Allocation | Randomized |
| Primary purpose | Treatment |
| Enrollment | 2124 |
| Registered primary endpoint | Percentage of Participants With Clinically Significant Bleeding |
| Primary endpoint time frame | Up to Month 12 |
| Registered endpoint type | Binary |
| Posted statistical analyses | 18 |
| Posted outcome measures | 9 |
| Trial status | Completed |
2. Clinical Question
The statistical question was whether either rivaroxaban-based treatment strategy differed from vitamin K antagonist therapy in the time to clinically significant bleeding during the registered follow-up period of up to Month 12.
Population
Participants with atrial fibrillation who undergo percutaneous coronary intervention.
Intervention strategies
Rivaroxaban 15 mg, or rivaroxaban 2.5 mg twice daily/15 mg once daily, within the trial's three-arm design.
Comparator
Vitamin K antagonist (VKA) therapy.
Primary question
How did the rivaroxaban-based strategies compare with VKA therapy for clinically significant bleeding up to Month 12?
3. Trial Design
Rivaroxaban 15 mg
- Rivaroxaban 15 mg
- One of the two rivaroxaban-based randomized strategies
- Compared directly with the VKA strategy in the posted analyses
Rivaroxaban 2.5 mg BID / 15 mg QD
- Rivaroxaban 2.5 mg twice daily/15 mg once daily
- Second rivaroxaban-based randomized strategy
- Compared directly with the VKA strategy in the posted analyses
Antiplatelet therapy
- Aspirin (ASA)
- Clopidogrel
- Prasugrel
- Ticagrelor
Vitamin K antagonist
- Vitamin K antagonist (VKA)
- Randomized comparator strategy
4. Randomization, Treatment Structure, and Analysis Population
The trial was randomized and parallel, with no masking. The ClinicalTrials.gov record identifies three arms and 2124 enrolled participants. The posted primary and secondary statistical analyses used a safety analysis set defined as all randomized participants who received at least 1 dose of study drug.
| Element | Registry information |
|---|---|
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Arms | 3 |
| Safety analysis set | All randomized participants who received at least 1 dose of study drug |
| Endpoint analysis framework | Time-to-event analysis using the log-rank test and hazard ratio |
The analysis population is important because the primary posted estimates are not described as an all-randomized intention-to-treat analysis. Instead, the registry explicitly defines the safety analysis set as randomized participants who received at least one dose of study drug. That population definition should remain attached to the reported hazard ratios when interpreting them.
5. Primary Endpoint
The registered primary endpoint was Percentage of Participants With Clinically Significant Bleeding, with a time frame of Up to Month 12. Although the registry classifies the registered endpoint type as binary, the posted statistical analyses treat the endpoint as a time-to-event outcome and use log-rank testing with hazard ratios.
| Endpoint | Registry definition / analysis |
|---|---|
| Clinically significant bleeding | Composite of TIMI major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA) |
| TIMI major bleeding | Any symptomatic intracranial hemorrhage, or clinically overt signs of hemorrhage, including imaging, associated with a drop in hemoglobin of ≥5 grams per deciliter (g/dL) (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of >=15 percent (%)). TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to less than (\<) 5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to \<15 percent). A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event. |
| Time frame | Up to Month 12 |
| Registered endpoint type | Binary |
| Posted analysis type | Time-to-event |
| Statistical method | Log-rank test |
| Effect measure | Hazard ratio |
The composite construction is statistically important. A participant can experience clinically significant bleeding by meeting one of several component definitions. The composite therefore summarizes time to the first qualifying event under the endpoint definition rather than representing a single biological event type.
6. Primary Results
Rivaroxaban 15 mg vs Vitamin K Antagonist
Hazard ratio for clinically significant bleeding
95% CI: 0.47–0.76 · P < 0.001
Time frame: Up to Month 12 · Two-sided 95% confidence interval
The posted analysis compared rivaroxaban 15 mg with VKA using the log-rank test in the safety analysis set. The estimated hazard ratio was 0.59, with a two-sided 95% confidence interval from 0.47 to 0.76 and P < 0.001.
An HR of 0.59 means that, within the time-to-event model used for this comparison, the estimated instantaneous hazard of clinically significant bleeding was approximately 59% as high in the rivaroxaban 15 mg group as in the VKA group. Expressed as a relative model-based quantity, this corresponds to an estimated 41% lower hazard.
It does not mean that 41% of participants avoided bleeding, that the absolute probability of bleeding was reduced by 41 percentage points, or that every participant experienced the same relative reduction.
The 95% CI of 0.47–0.76 describes statistical uncertainty around the estimated hazard ratio. Because the entire interval is below 1, the interval is consistent with a lower estimated hazard in the rivaroxaban 15 mg group under this analysis.
The P < 0.001 value addresses the statistical evidence against the tested null comparison under the analysis framework. A p-value does not measure the magnitude of the treatment effect and should not be read as the probability that the treatment effect is real.
The interpretation also depends on censoring, the analysis population, and the assumptions underlying a hazard-ratio representation of the event process. The registry reports a hazard ratio but does not provide enough information in the ClinicalTrials.gov record to independently assess the proportional-hazards assumption.
Rivaroxaban 2.5 mg BID / 15 mg QD vs Vitamin K Antagonist
Hazard ratio for clinically significant bleeding
95% CI: 0.5–0.8 · P < 0.001
Time frame: Up to Month 12 · Two-sided 95% confidence interval
The second primary comparison evaluated the rivaroxaban 2.5 mg twice daily/15 mg once daily strategy against VKA. The log-rank analysis produced an estimated hazard ratio of 0.63, with a two-sided 95% confidence interval from 0.5 to 0.8 and P < 0.001.
An HR of 0.63 indicates an estimated instantaneous hazard of clinically significant bleeding approximately 63% as high in the rivaroxaban strategy as in the VKA group. As a relative model-based interpretation, that corresponds to an estimated 37% lower hazard.
This is a relative time-to-event measure, not an absolute risk reduction. It does not tell us directly how many fewer participants experienced clinically significant bleeding, nor does it imply that the same percentage reduction applied to every individual.
The 95% CI of 0.5–0.8 gives a range of statistical uncertainty around the estimated hazard ratio. Its endpoints remain below 1, so the reported interval is compatible with a lower estimated hazard under the specified comparison.
The P < 0.001 result provides evidence against the null hypothesis used in the superiority analysis, but it does not quantify clinical importance or effect size. The hazard ratio and its confidence interval provide that effect-size information.
As with the first primary comparison, interpretation requires attention to the safety analysis population and the time-to-event framework. The ClinicalTrials.gov record does not provide a reconstructed Kaplan-Meier curve or enough individual-level event and censoring information to independently reproduce the estimate.
7. Secondary Bleeding Results
The registry contains additional time-to-event analyses for TIMI major bleeding, TIMI minor bleeding, and bleeding requiring medical attention. These analyses use the same safety analysis set and the log-rank test, with hazard ratios and two-sided 95% confidence intervals.
TIMI Major Bleeding
| Comparison | HR | 95% CI | P-value |
|---|---|---|---|
| Rivaroxaban 15 mg vs VKA | 0.66 | 0.33–1.31 | 0.234 |
| Rivaroxaban 2.5 mg BID / 15 mg QD vs VKA | 0.57 | 0.28–1.16 | 0.114 |
Both estimates are below 1, but the corresponding confidence intervals include 1. The registry reports P = 0.234 for the first comparison and P = 0.114 for the second. These are superiority analyses, and the ClinicalTrials.gov record does not provide evidence that should be interpreted independently of the broader multiplicity and precision considerations of a trial containing multiple endpoint comparisons.
TIMI Minor Bleeding
| Comparison | HR | 95% CI | P-value |
|---|---|---|---|
| Rivaroxaban 15 mg vs VKA | 0.51 | 0.2–1.28 | 0.144 |
| Rivaroxaban 2.5 mg BID / 15 mg QD vs VKA | 0.5 | 0.2–1.26 | 0.134 |
The estimated hazards were approximately one-half of the VKA comparison hazard for both rivaroxaban strategies, but the confidence intervals are wide and include 1. The width of these intervals is an important part of the interpretation: a point estimate alone can give a false impression of precision when relatively uncommon events are being analyzed.
Bleeding Requiring Medical Attention
| Comparison | HR | 95% CI | P-value |
|---|---|---|---|
| Rivaroxaban 15 mg vs VKA | 0.61 | 0.47–0.8 | <0.001 |
| Rivaroxaban 2.5 mg BID / 15 mg QD vs VKA | 0.67 | 0.52–0.86 | 0.002 |
For bleeding requiring medical attention, both posted estimates are below 1 and both confidence intervals exclude 1. The reported P-values are <0.001 and 0.002, respectively. These analyses are secondary endpoints rather than the registered primary endpoint, so their statistical interpretation should remain distinct from the primary hypothesis tests.
8. Cardiovascular Event Results
The registry also reports time-to-event analyses of a composite of adverse cardiovascular events, cardiovascular death, myocardial infarction, stroke, and stent thrombosis. These estimates are particularly useful for illustrating why a trial can show different statistical behavior across bleeding and cardiovascular endpoints.
Composite of Cardiovascular Death, Myocardial Infarction, and Stroke
| Comparison | HR | 95% CI | P-value |
|---|---|---|---|
| Rivaroxaban 15 mg vs VKA | 1.08 | 0.69–1.68 | 0.75 |
| Rivaroxaban 2.5 mg BID / 15 mg QD vs VKA | 0.93 | 0.59–1.48 | 0.765 |
The first comparison has an estimated HR above 1, whereas the second has an estimate below 1. Both confidence intervals include 1. The estimates therefore do not establish a statistically distinguishable difference in the composite endpoint under these posted superiority analyses.
An HR of 1.08 should not be interpreted as proof that the treatment has an 8% higher absolute cardiovascular risk. It is a relative hazard estimate, and its 95% CI of 0.69–1.68 spans values below and above 1. The uncertainty interval is therefore essential to understanding the estimate.
Similarly, an HR of 0.93 is close to 1, but the appropriate interpretation is not simply "no effect." The confidence interval of 0.59–1.48 indicates that the data are compatible with a range of relative hazard values under the model.
Cardiovascular Death
| Comparison | HR | 95% CI | P-value |
|---|---|---|---|
| Rivaroxaban 15 mg vs VKA | 1.29 | 0.59–2.8 | 0.523 |
| Rivaroxaban 2.5 mg BID / 15 mg QD vs VKA | 1.19 | 0.54–2.62 | 0.664 |
These cardiovascular-death estimates have substantially wide confidence intervals relative to the point estimates. That is a reminder that precision depends on the amount of information available for a particular endpoint, not merely on the total randomized sample size.
Myocardial Infarction
| Comparison | HR | 95% CI | P-value |
|---|---|---|---|
| Rivaroxaban 15 mg vs VKA | 0.86 | 0.46–1.59 | 0.625 |
| Rivaroxaban 2.5 mg BID / 15 mg QD vs VKA | 0.75 | 0.4–1.42 | 0.374 |
Stroke
| Comparison | HR | 95% CI | P-value |
|---|---|---|---|
| Rivaroxaban 15 mg vs VKA | 1.07 | 0.39–2.96 | 0.891 |
| Rivaroxaban 2.5 mg BID / 15 mg QD vs VKA | 1.36 | 0.52–3.58 | 0.53 |
Stent Thrombosis
| Comparison | HR | 95% CI | P-value |
|---|---|---|---|
| Rivaroxaban 15 mg vs VKA | 1.2 | 0.32–4.45 | 0.79 |
| Rivaroxaban 2.5 mg BID / 15 mg QD vs VKA | 1.44 | 0.4–5.09 | 0.574 |
The stent-thrombosis estimates illustrate an especially important statistical principle: a wide confidence interval can contain both a potentially lower and a potentially higher hazard. A nonsignificant P-value does not demonstrate equivalence, and a point estimate above 1 does not by itself establish harm.
9. Safety Results
The ClinicalTrials.gov record reports serious adverse events by randomized treatment group using affected participants over participants at risk. These counts should be interpreted as safety summaries rather than as the same time-to-event estimands used for the primary bleeding analyses.
| Randomized strategy | Serious adverse events | At risk |
|---|---|---|
| Rivaroxaban 15 mg | 237 | 696 |
| Rivaroxaban 2.5 mg BID / 15 mg | 225 | 706 |
| Vitamin K Antagonist (VKA) | 271 | 697 |
The registry reports these figures as 237/696, 225/706, and 271/697, respectively. They are descriptive arm-level safety counts. They should not be converted here into new percentages or compared through a newly calculated statistical test because the ClinicalTrials.gov record does not report such an analysis.
10. Statistical Methodology
Time-to-event analysis
The primary and posted secondary analyses treat clinically significant bleeding and the other listed outcomes as time-to-event endpoints. Instead of considering only whether an event occurred by Month 12, the analysis uses information about when the event occurred and accommodates participants whose event status is censored during follow-up.
Here T represents the time to the event of interest. The survival function is the probability of remaining event-free beyond time t.
This framework is especially useful when participants have different follow-up times. A binary endpoint discards the timing information; a time-to-event analysis retains it and can incorporate right-censored observations.
Log-rank test
The registry identifies the log-rank test as the reported method for all 18 posted statistical analyses. Conceptually, the log-rank test compares the observed and expected numbers of events between treatment groups across event times.
The comparison is based on the ordering of event times and the numbers at risk, rather than simply comparing final percentages at a single time point.
Because the analysis uses the full follow-up structure, the log-rank test is not equivalent to a simple chi-square comparison of the percentage of participants with an event by Month 12.
Hazard ratio
The effect measure reported for every registry-reported statistical analysis is the hazard ratio. An HR below 1 indicates a lower estimated instantaneous event hazard in the numerator treatment group relative to the comparator; an HR above 1 indicates a higher estimated instantaneous event hazard.
The hazard ratio is a relative time-to-event measure. It is not a relative risk, an absolute risk difference, or a probability that an individual patient will experience an event.
Confidence intervals
The reported primary analyses use two-sided 95% confidence intervals. The interval describes uncertainty around the estimated hazard ratio under the statistical model and sampling framework. It does not describe the range of effects that individual participants experienced.
Superiority testing
The analyses posted on ClinicalTrials.gov are identified as superiority hypotheses. That means the statistical question is whether the treatment groups differ under the prespecified superiority framework, rather than whether one strategy meets a predefined non-inferiority margin.
Safety analysis population
The posted analyses use the safety analysis set: all randomized participants who received at least 1 dose of study drug. This population definition is part of the estimand context and should be reported alongside the hazard ratios rather than treated as a minor technical detail.
11. Statistical Methods Explained
Why was a log-rank test used?
Because the registry analyses treat the outcomes as time-to-event endpoints. A log-rank test uses information about event timing and numbers at risk throughout follow-up, making it appropriate for comparing event-time distributions between randomized groups.
What does an HR of 0.59 mean?
An HR of 0.59 means the estimated instantaneous hazard in the rivaroxaban 15 mg group was 0.59 times the corresponding hazard in the VKA group under the fitted time-to-event framework. It can be expressed as an estimated 41% lower hazard, but it should not be translated into a 41% absolute reduction in the number of participants experiencing bleeding.
Why is the confidence interval as important as the point estimate?
The HR is only one estimate from the observed data. The 95% CI communicates how precisely that effect was estimated. For example, the primary HR of 0.59 has a 95% CI of 0.47–0.76, whereas the TIMI major bleeding HR of 0.66 has a much wider 95% CI of 0.33–1.31. The latter point estimate alone would conceal substantial uncertainty.
Why doesn't P < 0.001 measure effect size?
A p-value addresses evidence against a null hypothesis within a specified statistical framework. It does not say whether an effect is large or small. Effect size is described by the hazard ratio, while its precision is described by the confidence interval. Sample size and event information can also influence the p-value.
Why can an HR above 1 still be statistically inconclusive?
Consider the cardiovascular-death HR of 1.29 for rivaroxaban 15 mg versus VKA. Its 95% CI is 0.59–2.8 and P = 0.523. Because the interval includes 1, the data do not establish a statistically distinguishable difference under this superiority analysis. The point estimate alone is insufficient.
Why does the registered endpoint type say binary when the posted analysis is time-to-event?
The ClinicalTrials.gov record classifies the registered primary endpoint as Binary while separately reporting that the statistical analyses use a time-to-event framework. These are different descriptions of the endpoint: one concerns the registry's endpoint classification, while the posted analysis incorporates event timing and uses a log-rank test with a hazard ratio.
12. Interpreting the Primary Results Together
| Primary comparison | HR | 95% CI | P-value | Statistical reading |
|---|---|---|---|---|
| Rivaroxaban 15 mg vs VKA | 0.59 | 0.47–0.76 | <0.001 | Estimated hazard below VKA; CI excludes 1 |
| Rivaroxaban 2.5 mg BID / 15 mg QD vs VKA | 0.63 | 0.5–0.8 | <0.001 | Estimated hazard below VKA; CI excludes 1 |
The two primary estimates are directionally similar: both are below 1, both have two-sided 95% confidence intervals entirely below 1, and both have P < 0.001. The statistical interpretation is therefore internally consistent across the two posted primary comparisons.
That consistency should not be expanded into claims about endpoints that were not statistically significant. For example, the cardiovascular composite analyses produced HRs of 1.08 and 0.93 with confidence intervals that include 1. The primary bleeding result and the cardiovascular secondary analyses answer different questions and should be kept separate.
The primary HRs summarize relative event hazards. Without event-free survival estimates, cumulative incidence values, or the underlying participant-level event and censoring information, the ClinicalTrials.gov record does not support calculation of absolute risk differences or numbers needed to treat.
The registry specifically states that assignment to 1, 6, or 12 months of DAPT was based on clinician choice and was not randomized. Consequently, that treatment-duration decision should not be interpreted as though it were another randomized comparison embedded within the trial.
13. Multiplicity and Multiple Endpoint Comparisons
The ClinicalTrials.gov record contains 18 statistical analyses across the primary and secondary endpoints. The primary endpoint has two posted superiority comparisons against VKA, while multiple secondary bleeding and cardiovascular outcomes were also analyzed.
| Analysis family | Number represented in the ClinicalTrials.gov record | Interpretive role |
|---|---|---|
| Primary endpoint comparisons | 2 | Primary superiority comparisons |
| TIMI major bleeding | 2 | Secondary endpoint comparisons |
| TIMI minor bleeding | 2 | Secondary endpoint comparisons |
| BRMA | 2 | Secondary endpoint comparisons |
| Cardiovascular death / MI / stroke composite | 2 | Secondary endpoint comparisons |
| Cardiovascular death | 2 | Secondary endpoint comparisons |
| Myocardial infarction | 2 | Secondary endpoint comparisons |
| Stroke | 2 | Secondary endpoint comparisons |
| Stent thrombosis | 2 | Secondary endpoint comparisons |
When many statistical comparisons are performed, the interpretation of individual p-values depends on the prespecified multiplicity strategy. The ClinicalTrials.gov record identifies the analyses as superiority tests but do not provide an alpha-allocation or multiplicity-adjustment procedure. Therefore, the reported p-values should be presented as reported rather than retrospectively treated as though a specific multiplicity correction had been documented in the ClinicalTrials.gov record.
14. Crossover, Treatment Duration, and Causal Interpretation
The registry caveat identifies an important nonrandomized component of the trial: the duration of DAPT at 1, 6, or 12 months was determined by clinician choice. This creates an important distinction between the randomized treatment strategy and treatment-duration decisions made within the clinical setting.
Randomized component
The main trial allocation was randomized across three treatment strategies.
Nonrandomized component
DAPT duration of 1, 6 or 12 months was based upon clinician choice and was not randomized.
Statistical implication
Associations involving clinician-selected DAPT duration cannot automatically be given the causal interpretation of the randomized treatment comparison.
Interpretive boundary
The ClinicalTrials.gov record does not provide a separate randomized analysis of DAPT duration.
The registry also notes that there was not sufficient power to definitively assess efficacy because of the modest number of adverse cardiovascular events. This is a precision issue: a trial can have a substantial randomized enrollment while still having limited information for relatively uncommon cardiovascular outcomes.
15. Why Event Counts Matter More Than Enrollment Alone
The PIONEER AF-PCI data illustrate an important distinction in clinical-trial statistics: the number randomized is not the same as the amount of information available for every endpoint.
There were 2124 enrolled participants, but cardiovascular death, myocardial infarction, stroke, and stent thrombosis are individual event categories with comparatively uncertain estimates in the analyses posted on ClinicalTrials.gov. The resulting confidence intervals are notably broad for several of these outcomes.
| Endpoint | Rivaroxaban 15 mg vs VKA | Rivaroxaban 2.5 mg BID / 15 mg QD vs VKA |
|---|---|---|
| Primary clinically significant bleeding | 0.59 (0.47–0.76) | 0.63 (0.5–0.8) |
| TIMI major bleeding | 0.66 (0.33–1.31) | 0.57 (0.28–1.16) |
| Cardiovascular death | 1.29 (0.59–2.8) | 1.19 (0.54–2.62) |
| Stroke | 1.07 (0.39–2.96) | 1.36 (0.52–3.58) |
| Stent thrombosis | 1.2 (0.32–4.45) | 1.44 (0.4–5.09) |
The contrast is educational. The primary bleeding estimates are comparatively precise, whereas several individual cardiovascular outcomes have wide intervals. The registry's own caveat that there was not sufficient power to definitively assess efficacy due to the modest number of adverse cardiovascular events is therefore directly relevant to interpretation.
16. What the Hazard Ratio Does — and Does Not — Mean in PIONEER AF-PCI
The primary HR of 0.59 is a relative estimate of the event hazard for clinically significant bleeding. It means the estimated instantaneous hazard was about 59% of that in the VKA comparator under the reported time-to-event analysis.
It does not mean that 59% of participants bled, that 41% of participants were protected from bleeding, or that the absolute probability of bleeding fell by 41 percentage points.
The 95% CI of 0.47–0.76 expresses uncertainty around the HR estimate. The interval does not describe individual patient responses. It also does not mean that there is a 95% probability that the true HR lies inside this particular interval under every interpretation of probability.
The primary P < 0.001 is evidence against the null hypothesis in the reported superiority analysis. It does not measure clinical importance, does not measure the probability that the treatment is effective, and should not replace the HR and confidence interval when communicating the magnitude and precision of the result.
A single HR is easiest to interpret as a common relative hazard over time when the proportional-hazards assumption is reasonable. The ClinicalTrials.gov record reports the HR but do not provide enough information to independently test that assumption. A hazard ratio should therefore be understood as a model-based summary rather than a universal percentage reduction applying identically at every time point.
17. Limitations
- Clinician-selected DAPT duration: allocation to 1, 6 or 12 months of DAPT was based upon clinician choice and was not randomized.
- Limited efficacy power: the registry states that there was not sufficient power to definitively assess efficacy because of the modest number of adverse cardiovascular events.
- Analysis population: the posted analyses use the safety analysis set, defined as randomized participants who received at least 1 dose of study drug. This differs conceptually from simply describing all randomized participants.
- Wide intervals for uncommon outcomes: several cardiovascular endpoint estimates have broad confidence intervals, limiting precision.
- Multiple analyses: 18 statistical analyses were posted across primary and secondary outcomes. The ClinicalTrials.gov record does not specify a multiplicity-adjustment procedure, so individual secondary p-values require appropriate context.
- Hazard-ratio assumptions: the registry reports hazard ratios, but the ClinicalTrials.gov record does not permit an independent assessment of proportional hazards.
- Composite endpoint: clinically significant bleeding combines TIMI major bleeding, TIMI minor bleeding, and BRMA, so the composite represents multiple clinically defined event types rather than one homogeneous outcome.
- Different statistical descriptions: the registry classifies the registered primary endpoint as Binary while the posted analyses use a time-to-event framework. Both descriptions should be retained rather than silently replacing one with the other.
18. Why This Trial Matters Statistically
PIONEER AF-PCI is a useful statistical teaching case because it combines randomized treatment allocation, multiple treatment strategies, a composite bleeding endpoint, time-to-event analysis, hazard ratios, secondary cardiovascular outcomes, safety-population definitions, and a clinically selected component of treatment duration.
| Concept | How it appears in PIONEER AF-PCI |
|---|---|
| Randomization | Three-arm randomized parallel design |
| Time-to-event endpoints | Primary and secondary posted analyses use event timing through follow-up |
| Log-rank test | Reported method for all registry-reported statistical analyses |
| Hazard ratio | Effect measure for every registry-reported statistical analysis |
| Confidence interval | Two-sided 95% intervals reported for the primary and secondary comparisons |
| Composite endpoint | Clinically significant bleeding combines three bleeding categories |
| Superiority testing | Primary and secondary analyses are identified as superiority hypotheses |
| Safety population | Randomized participants receiving at least 1 dose of study drug |
| Nonrandomized treatment component | DAPT duration was selected by clinician choice |
| Limited event information | Registry caveat notes insufficient power for definitive efficacy assessment because of modest cardiovascular event counts |
| Multiplicity | 18 statistical analyses span the primary and secondary outcomes |
19. Statistical Interpretation of Bleeding vs Cardiovascular Outcomes
One of the most instructive features of the ClinicalTrials.gov record is that the statistical estimates are not uniform across endpoint families. The two primary clinically significant bleeding comparisons have HRs below 1 with confidence intervals excluding 1. Several individual cardiovascular outcomes have confidence intervals that are much wider and include 1.
Bleeding endpoints
The primary HRs are 0.59 and 0.63, with two-sided 95% confidence intervals of 0.47–0.76 and 0.5–0.8, respectively.
Cardiovascular endpoints
Individual cardiovascular outcomes have estimates ranging across values below and above 1, with several broad confidence intervals.
What this demonstrates
A trial's statistical conclusions can differ by endpoint because the underlying event processes and amount of event information differ.
What it does not demonstrate
A nonsignificant secondary endpoint does not by itself establish equivalence, and a significant endpoint does not automatically become a separate primary claim.
The registry caveat provides an explicit reason for caution on efficacy: there was not sufficient power to definitively assess efficacy because of the modest number of adverse cardiovascular events. Statistically, this is consistent with the broad confidence intervals observed for several cardiovascular outcomes.
20. Understanding Censoring in This Trial
Because the posted analyses are time-to-event analyses, participants do not necessarily need to experience an event for their data to contribute information. A participant who remains event-free through the available observation period can contribute follow-up time until censoring.
This is why a time-to-event analysis can use different follow-up durations without simply treating participants with shorter observation as though they had completed the entire study period.
The ClinicalTrials.gov record does not provide individual censoring dates or event histories, so a Kaplan-Meier curve cannot be reconstructed from the registry summaries alone. The appropriate statistical interpretation is therefore based on the reported hazard ratios, confidence intervals, p-values, and documented analysis method.
21. Results in Context of the Registered Endpoint
| Question | Answer from the ClinicalTrials.gov record |
|---|---|
| What was the registered primary endpoint? | Percentage of Participants With Clinically Significant Bleeding |
| What was the registered time frame? | Up to Month 12 |
| How was clinically significant bleeding defined? | Composite of TIMI major bleeding, TIMI minor bleeding, and BRMA |
| How was the posted endpoint analyzed? | Time-to-event analysis using the log-rank test |
| What effect measure was reported? | Hazard ratio |
| What was the first primary comparison? | Rivaroxaban 15 mg vs VKA |
| What was the second primary comparison? | Rivaroxaban 2.5 mg BID / 15 mg QD vs VKA |
| Were results posted? | Yes |
This alignment between the registered endpoint and the posted statistical analysis is useful for teaching: the endpoint can be described as the occurrence of a clinically defined composite while the statistical analysis uses the additional dimension of time until the first qualifying event.
22. Longitudinal Trial History
Trial start
PIONEER AF-PCI began enrollment under the registered randomized phase 3 design.
Primary completion
The registry lists July 28, 2016 as the primary completion date.
Results posted
The registry contains 9 posted outcome measures and 18 posted statistical analyses, including 2 primary-endpoint analyses.
23. Important Statistical Distinctions
Hazard vs probability
A hazard ratio compares instantaneous event hazards. It is not the same as comparing cumulative probabilities at Month 12.
Point estimate vs precision
The HR is the point estimate; the 95% CI shows its statistical precision. Both should be read together.
Primary vs secondary
The two clinically significant bleeding analyses are primary; the TIMI and cardiovascular analyses are secondary.
Randomized vs clinician-selected
The three-arm treatment allocation was randomized, whereas DAPT duration was based on clinician choice.
24. Limitations of the Available Registry Results
The ClinicalTrials.gov record is sufficient to describe the reported statistical analyses, but it does not contain individual-level event histories, Kaplan-Meier coordinates, or enough information to reconstruct the full survival curves. It also does not provide a documented multiplicity-adjustment procedure, detailed model diagnostics, or a separate randomized comparison of DAPT duration.
Accordingly, this page deliberately does not manufacture absolute event rates, reconstructed survival curves, additional subgroup analyses, or new statistical tests. Doing so would create numbers that are not present in the ClinicalTrials.gov record and could give the appearance of greater precision than the registry record supports.
25. Related Tutorials
Learn more about the methods used in this trial:
26. Related Calculators
27. Sources
- ClinicalTrials.gov: PIONEER AF-PCI, NCT01830543.
- Linked publication: PubMed PMID 31707805.
- Linked publication: PubMed PMID 31535314.
- Linked publication: PubMed PMID 30704287.
- Linked publication: PubMed PMID 30015064.
- Linked publication: PubMed PMID 29943350.
Continue through Clinical Biostats
Build from the statistical concepts used in this trial into deeper tutorials, calculators, and clinical-trial analysis workflows.
28. Record Summary
PIONEER AF-PCI provides a compact teaching example of how randomized clinical-trial data can be analyzed across several related but distinct endpoint families. The registered primary endpoint was clinically significant bleeding through Month 12, defined as a composite of TIMI major bleeding, TIMI minor bleeding, and bleeding requiring medical attention. The posted analyses treated that endpoint as time-to-event and used log-rank testing with hazard ratios. The two primary comparisons produced HRs of 0.59 and 0.63, each with a two-sided 95% confidence interval entirely below 1 and P < 0.001.
The secondary results demonstrate why statistical interpretation cannot stop at the primary p-value. TIMI major and minor bleeding estimates were less precise, while bleeding requiring medical attention showed HRs of 0.61 and 0.67. Cardiovascular outcomes had different estimates and, for several individual endpoints, substantially wider confidence intervals. The registry explicitly cautions that the trial did not have sufficient power to definitively assess efficacy because of the modest number of adverse cardiovascular events.
The trial also illustrates the importance of separating randomized from nonrandomized components. The principal three-arm allocation was randomized, whereas the choice of 1, 6 or 12 months of DAPT was based upon clinician choice. For statistical interpretation, that distinction is essential because randomization is what supports the strongest causal comparison between the randomized treatment strategies.